As HIV Patients Live Longer, Certain Cancer Risks Rise

Share this content:
As HIV Patients Live Longer, Certain Cancer Risks Rise
As HIV Patients Live Longer, Certain Cancer Risks Rise

TUESDAY, Oct. 6, 2015 (HealthDay News) -- Antiretroviral therapy has extended the lives of people with HIV, but living longer may increase these patients' risk for certain cancers, according to a study published in the Oct. 6 issue of the Annals of Internal Medicine.

Researchers focused on 86,620 HIV patients and 196,987 non-HIV adults who participated in the North American AIDS Cohort Collaboration on Research and Design study between 1996 and 2009. The team tracked the rate of nine types of cancer, including Kaposi sarcoma, non-Hodgkin's lymphoma, Hodgkin's lymphoma, lung cancer, anal cancer, colorectal cancer, liver cancer, oral cavity/pharyngeal cancer, and melanoma. The authors also calculated each group's total cancer risk until age 75.

The team determined that, compared with non-HIV participants, cancer rates for HIV patients were higher across all nine cancers in every year examined. In particular, by 2009, HIV patients were identified as having a one in 25 lifetime risk for developing Kaposi sarcoma, non-Hodgkin's lymphoma, or lung cancer. However, declines were seen in the rate of Kaposi sarcoma -- by 6 percent a year -- and non-Hodgkin's lymphoma, which fell by 8 percent a year. No change was noted for lung cancer, Hodgkin's lymphoma, and melanoma. But anal cancer and liver cancer incidence each went up by 6 percent a year, while colorectal cancer rose by 5 percent annually.

As HIV has become a long-term chronic condition, "all sorts of health issues that patients and their doctors didn't think they had to worry about are now something they have to worry about," study coauthor Michael Horberg, M.D., immediate past chair of the HIV Medicine Association and Kaiser Permanente's director of HIV/AIDS, told HealthDay. "It's no longer enough just to survive," he added. "You want to survive well."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA OKs Doptelet for Liver Dz Patients Undergoing Procedures

FDA OKs Doptelet for Liver Dz Patients Undergoing ...

Doptelet reduces the need for platelet transfusion or any rescue therapy on day of procedure

Slower Decline in Lung Function With Anthocyanin Intake

Slower Decline in Lung Function With Anthocyanin Intake

Slower annual rates of decline in FEV1 and FVC for those in highest quartile of anthocyanin intake

Bioengineering Feasible for Airway Reconstruction

Bioengineering Feasible for Airway Reconstruction

Bioengineered tracheal and bronchial reconstruction reported using stented aortic matrices

is free, fast, and customized just for you!

Already a member?

Sign In Now »